Adjuvant anthracycline therapy as a prognostic factor in metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 66, Issue 1, 2001, Pages 33-39

  Alba, E ^a   Ribelles, N ^a   Sevilla, I ^a   Rueda, A ^a   Alonso, L ^a   Marquez, A ^a   Ruiz, I ^a   Miramon J ^a  

^a HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

Author keywords

Adjuvant therapy; Anthracyclines; Breast cancer; Chemotherapy

Indexed keywords

ANTHRACYCLINE;

ADJUVANT THERAPY; ADULT; AGE; ARTICLE; AXILLARY LYMPH NODE; BREAST CARCINOMA; CANCER GRADING; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SURGICAL TECHNIQUE; TREATMENT OUTCOME;

ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 0035042773     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1010616532332     Document Type: Article

References (32)

1. Tamoxifen for early breast cancer: An overview of the randomised trials
2. Polychemotherapy for early breast cancer: An overview of the randomised trials
3. Significance of relapse after adjuvant treatment with combination chemotherapy or 5-fluoruracil alone in high risk breast cancer
4. Possible adverse effect of failed adjuvant chemotherapy on the prognosis of women receiving consecutive chemotherapy for recurrent breast cancer
5. The effect of prior adjuvant chemotherapy on survival in metastatic breast cancer
6. Results of salvage hormonal therapy and salvage chemotherapy in women failing adjuvant chemotherapy after mastectomy for breast cancer
7. Prognostic factors in metastatic breast cancer treated with combination chemotherapy
8. Diverse prognosis in metastatic breast cancer: Who should be offered alternative initial therapy
9. Study of prognostic factors in the response of first line chemotherapy in advanced breast cancer
10. Survival after first recurrence of breast cancer
11. The influence of adjuvant chemotherapy on outcome after relapse for patients with breast cancer
12. Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer
13. Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxor ubicin and fiuoruracil in patients with metastatic breast cancer
14. Dose response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: A randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group
15. Construction and validation of a practical prognostic index for patients with metastatic breast cancer
16. Management of breast cancer patients failing adjuvant chemotherapy with adryamicin-containing regimens
17. Response to secondary therapy in patients with adenocarcinoma of the breast previously treated with adjuvant chemotherapy
18. Salvage treatment of patients suffering relapse after adjuvant CMF chemotherapy
19. Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy
20. Cyclophosphamide and fluoruracil combined with mitoxantrone versus doxorubicin for breast cancer: Superiority of doxorubicin
21. Chemotherpy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens
22. Evaluation of survival data in two new rank order statistic arising in its consideration
23. Regression models and life tables
24. Survival from first recurrence: Relative importance of prognostic factors in 1015 breast cancer patients
25. Prognostic factors in recurrent breast cancer: Relationships to site of recurrence, disease-free interval, female sex, steroid receptors, ploidy and histological malignancy grading
26. Survival after first recurrence in breast cancer
27. The natural history of small breast cancer. David A. Karnofsky Memorial Lecture
28. Prognostic and predictive factors for patients with metastatic breast cancer undergoing agressive induction therapy followed by high dose chemotherapy with autologous stem cell support
29. The clonal evolution of tumor cell populations
30. Specific p53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients
31. P53-dependent apoptosis modulates the citotoxicity of anticancer agents
32. Higher frequency of gene amplification in breast cancer patients who received adjuvant chemotherapy